Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. 254. Sandset EC, Bath PM, Boysen G, Jatuzis D, K rv J, L ders S, Murray GD, Richter PS, Roine RO, Ter nt A, et al; SCAST Study Group. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. 255. Bath PM, Krishnan K. Interventions for deliberately altering blood pres- sure in acute stroke. Cochrane Database Syst Rev. 2014:CD000039. 256. Oh MS, Yu KH, Hong KS, Kang DW, Park JM, Bae HJ, Koo J, Lee J, Lee BC; Valsartan Efficacy oN modesT blood pressUre REduction in acute ischemic stroke (VENTURE) study group. Modest blood pressure reduction with valsartan in acute ischemic stroke: a prospective, random- ized, open-label, blinded-end-point trial. Int J Stroke. 2015;10:745 751. 257. LeeM,OvbiageleB,HongKS,WuYL,LeeJE,RaoNM,FengW,SaverJL. Effect of blood pressure lowering in early ischemic stroke: meta-analysis. 258. Woodhouse L, Scutt P, Krishnan K, Berge E, Gommans J, Ntaios G, Wardlaw J, Sprigg N, Bath PM; on behalf of the ENOS Investigators. Effect of hyperacute administration (within 6 hours) of transdermal glyc- eryl trinitrate, a nitric oxide donor, on outcome after stroke: subgroup analysis of the Efficacy of Nitric Oxide in Stroke (ENOS) Trial. Stroke. 259. Rai N, Prasad K, Bhatia R, Vibha D, Singh MB, Rai VK, Kumar A. Development and implementation of acute stroke care pathway in a ter- tiary care hospital in India: a cluster-randomized study. Neurol India. 260. Middleton S, McElduff P, Ward J, Grimshaw JM, Dale S, D Este C, Drury P, Griffiths R, Cheung NW, Quinn C, et al; QASC Trialists Group. Implementation of evidence-based treatment protocols to manage fever, hyperglycaemia, and swallowing dysfunction in acute stroke (QASC): a cluster randomised controlled trial. Lancet. 2011;378:1699 1706. doi: 261. 